JOHNSON & JOHNSON

Insider buying spree: Pinto Daniel E adds 1,445 J&J DSUs—$646 m value—showing long‑term confidence amid stable share price and a strong research pipeline.

Johnson & Johnson insider trades reveal a buy‑sell cycle: EVP Taubert bought low, sold high, and exercised options—insights for investors on J&J’s long‑term confidence.

Insider sales by J&J CEO Duato Joaquin reveal routine portfolio tweaks, not a red flag for investors.

Johnson & Johnson insider trades reveal liquidity moves, not long‑term bets. Discover what Wengel Kathryn E’s round‑trip buy/sell means for investors and the company’s growth strategy.

Insider buying in Johnson & Johnson’s DSUs shows top‑level confidence in its oncology pipeline and steady dividend, signaling potential upside for defensive investors.

Johnson & Johnson insider sale during Kenvue exchange: small 11‑share deal amid broader executive activity—investors weigh short‑term sentiment vs. strong long‑term fundamentals.

CEO Duato Joaquin sells 100k J&J shares—what does it signal for the company’s outlook? Get the inside scoop on the impact and what investors should watch for.